20/20 Biolabs Inc. (AIDX:NASDAQ) closed at $0.185 on November 16, 2026, down 9.45% on the day. The stock trades 99.6% below its 52-week high of $50.00 and 2.8% above its 52-week low of $0.180. Over the past year, it lost 99.2%. 20/20 Biolabs Inc. is part of the Health Care sector.
In 187 trading sessions since February 20, 2026, AIDX closed higher on 56 days (30%). Its best day was June 1, 2026 (+18.39%) and its worst was February 20, 2026 (-38.03%). The stock moved 10% or more in a single session 25 times. It opened at least 5% above the previous day's high 1 time.
20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
Find more stocks like AIDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.